Sector: Consumer Non-Cyclicals | Industry: Food Processing |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 3838 W Parkway Blvd SALT LAKE CITY UT 84120-6336 |
Tel: | N/A |
Website: | https://www.usana.com |
IR: | See website |
Key People | ||
Kevin G. Guest Executive Chairman of the Board | Brent L. Neidig Chief Commercial Officer | Jim H. Brown President, Chief Executive Officer |
G. Douglas Hekking Chief Financial Officer | Walter Noot Chief Operating Officer | Paul A. Jones Chief People Officer |
Daniel A. Macuga Chief Communications and Marketing Officer | Robert A. Sinnott Chief Scientific Officer | P. Joshua Foukas Chief Legal Officer, General Counsel and Corporate Secretary | David Mulham Chief Sales Officer |
Business Overview |
USANA Health Sciences, Inc. is a global direct-selling, personal health and wellness company that develops and manufactures science-based nutritional and personal care products. The Company operates through one segment: Direct-selling. Its two geographic regions include Asia Pacific, and Americas and Europe. The Company's product lines include USANA Nutritionals Optimizers, Essentials/CellSentials, foods, personal care, skin care, and all others. The USANA Nutritionals Optimizers consist of supplements designed to meet individual health and nutritional needs. The Essentials/CellSentials product line includes vitamin and mineral supplements that provide total body nutrition. Its food product line includes meal replacement shakes, snack bars, and other related products. It also offers products designed for prenatal, infant, and young-child age groups in China. It distributes products internationally through direct selling, which entails person-to-person marketing and selling of products. |
Financial Overview |
For the fiscal year ended 30 December 2023, USANA Health Sciences, Inc. revenues decreased 8% to $921M. Net income decreased 8% to $63.8M. Revenues reflect Greater China segment decrease of 5% to $475.1M, Americas and Europe segment decrease of 8% to $180.6M. Net income also reflects Interest expense increase of 36% to $262K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from $3.60 to $3.31. |
Employees: | 1,800 as of Feb 23, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $521.37M as of Dec 30, 2023 |
Annual revenue (TTM): | $921.01M as of Dec 30, 2023 |
EBITDA (TTM): | $105.81M as of Dec 30, 2023 |
Net annual income (TTM): | $63.79M as of Dec 30, 2023 |
Free cash flow (TTM): | $56.15M as of Dec 30, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 19,240,514 as of Feb 23, 2024 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |